3rd Circ. Refuses To Revive Novartis Labeling Suit
The Third Circuit on Wednesday upheld the dismissal of a deceased man's family's failure-to-warn suit against Novartis over high-blood-calcium treatment Zometa, saying that the family hadn't shown sufficient evidence of causation....To view the full article, register now.
Already a subscriber? Click here to view full article